rs759380437
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
rs771174392
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
rs147001633
|
|
|
0.800 |
GeneticVariation |
BEFREE |
AML cells with the R882H mutation have severely reduced de novo methyltransferase activity and focal hypomethylation at specific CpGs throughout AML cell genomes.
|
24656771 |
2014 |
rs147001633
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
AML cells with the R882H mutation have severely reduced de novo methyltransferase activity and focal hypomethylation at specific CpGs throughout AML cell genomes.
|
24656771 |
2014 |
rs147001633
|
|
|
0.800 |
GeneticVariation |
BEFREE |
R882H specific DNA hypermethylation events in AML patients were accompanied by R882H specific mis-regulation of several genes with strong cancer connection, which are potential downstream targets of R882H.
|
31620784 |
2019 |
rs147001633
|
|
A |
0.800 |
CausalMutation |
CLINVAR |
Cancer stem cells: Tracing clones.
|
22898540 |
2012 |
rs377577594
|
|
T |
0.710 |
CausalMutation |
CLINVAR |
Cancer stem cells: Tracing clones.
|
22898540 |
2012 |
rs147001633
|
|
|
0.800 |
GeneticVariation |
BEFREE |
DNMT3A R882H, a frequent mutation in acute myeloid leukemia (AML), plays a critical role in malignant hematopoiesis.
|
31703632 |
2019 |
rs147001633
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
DNMT3A mutations in acute myeloid leukemia.
|
21067377 |
2010 |
rs147001633
|
|
G |
0.800 |
CausalMutation |
CLINVAR |
DNMT3A mutations in acute myeloid leukemia.
|
21067377 |
2010 |
rs377577594
|
|
A |
0.710 |
CausalMutation |
CLINVAR |
DNMT3A mutations in acute myeloid leukemia.
|
21067377 |
2010 |
rs377577594
|
|
T |
0.710 |
CausalMutation |
CLINVAR |
DNMT3A mutations in acute myeloid leukemia.
|
21067377 |
2010 |
rs147001633
|
|
|
0.800 |
GeneticVariation |
BEFREE |
DNMT3A R882H occurs frequently in various cancers, including acute myeloid leukemia, and our results suggest that the effects of R882H and other <i>DNMT3A</i> mutations may go beyond changes in DNMT3A methylation activity.
|
31640986 |
2019 |
rs147001633
|
|
G |
0.800 |
CausalMutation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs147001633
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs377577594
|
|
A |
0.710 |
CausalMutation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs147001633
|
|
A |
0.800 |
CausalMutation |
CLINVAR |
Impact of genetic features on treatment decisions in AML.
|
22160010 |
2011 |
rs147001633
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Impact of genetic features on treatment decisions in AML.
|
22160010 |
2011 |
rs147001633
|
|
G |
0.800 |
CausalMutation |
CLINVAR |
Impact of genetic features on treatment decisions in AML.
|
22160010 |
2011 |
rs377577594
|
|
C |
0.710 |
CausalMutation |
CLINVAR |
Impact of genetic features on treatment decisions in AML.
|
22160010 |
2011 |
rs377577594
|
|
T |
0.710 |
CausalMutation |
CLINVAR |
Impact of genetic features on treatment decisions in AML.
|
22160010 |
2011 |
rs377577594
|
|
A |
0.710 |
CausalMutation |
CLINVAR |
Impact of genetic features on treatment decisions in AML.
|
22160010 |
2011 |
rs147001633
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients.
|
24606448 |
2014 |
rs377577594
|
|
A |
0.710 |
CausalMutation |
CLINVAR |
Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients.
|
24606448 |
2014 |
rs147001633
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Our results provided novel insight into the role of the DNMT3A R882H mutation in AML pathogenesis and suggested that targeting the cellular GSH synthetic pathway could enhance the current therapy for AML patients with the DNMT3A R882H mutation.
|
28418922 |
2017 |